| Market Cap | 4.17M | P/E | - | EPS this Y | -212.50% | Ern Qtrly Grth | - |
| Income | -75.49M | Forward P/E | -0.06 | EPS next Y | 10.00% | 50D Avg Chg | -95.00% |
| Sales | 12.69M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
| Dividend | N/A | Price/Book | 0.13 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 2.00 | Quick Ratio | 1.34 | Shares Outstanding | 140.03M | 52W Low Chg | 130.00% |
| Insider Own | 16.53% | ROA | -50.93% | Shares Float | 54.43M | Beta | 0.52 |
| Inst Own | 59.55% | ROE | -124.76% | Shares Shorted/Prior | 3.43M/1.70M | Price | 0.03 |
| Gross Margin | 41.75% | Profit Margin | - | Avg. Volume | 9,926,074 | Target Price | 5.33 |
| Oper. Margin | -938.18% | Earnings Date | Aug 9 | Volume | 66,303,236 | Change | 0.00% |
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology. Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| 5AM Partners IV, LLC | 10% Owner 10% Owner | Apr 10 | Sell | 0.12 | 16,544,113 | 1,985,294 | 200,000 | 04/12/23 |
| Brenner Erin K. | Chief Product Dev. O.. Chief Product Dev. Officer | Jan 14 | Option | 0.00 | 22,000 | 52,000 | 01/18/23 | |
| Maricich Yuri | Chief Medical Office.. Chief Medical Officer | Jan 14 | Option | 0.00 | 30,800 | 106,495 | 01/18/23 | |
| McCann Corey | President and CEO President and CEO | Jan 14 | Option | 0.00 | 88,000 | 8,245,565 | 01/18/23 | |
| GUIFFRE CHRISTOPHERD T | CFO, COO, Treas., &.. CFO, COO, Treas., & Asst. Sec. | Jan 14 | Option | 0.00 | 49,500 | 49,500 | 01/18/23 | |
| Snow Ellen | Chief Accounting Off.. Chief Accounting Officer | Jan 14 | Option | 0.00 | 20,320 | 31,345 | 01/18/23 | |
| Strandberg Julia | Chief Commercial Off.. Chief Commercial Officer | Jan 14 | Option | 0.00 | 33,000 | 41,300 | 01/18/23 | |
| O'Brien Ronan | GC, CCO & Secretary GC, CCO & Secretary | Jan 14 | Option | 0.00 | 30,800 | 30,800 | 01/18/23 | |
| Jeffery Katherine | Chief People Officer Chief People Officer | Jan 14 | Option | 0.00 | 15,400 | 15,400 | 01/18/23 | |
| 5AM Partners IV, LLC | 10% Owner 10% Owner | Nov 11 | Sell | 2.83 | 105,281 | 297,945 | 534,855 | 11/15/22 |
| 5AM Partners IV, LLC | 10% Owner 10% Owner | Oct 31 | Sell | 2.77 | 54,209 | 150,159 | 539,066 | 11/02/22 |
| 5AM Partners IV, LLC | 10% Owner 10% Owner | Sep 06 | Sell | 2.03 | 770,000 | 1,563,100 | 563,562 | 09/08/22 |
| 5AM Partners IV, LLC | 10% Owner 10% Owner | Aug 16 | Sell | 1.68 | 400,000 | 672,000 | 594,362 | 08/18/22 |